Publications by authors named "Gary T Anderson"
J Pharmacol Exp Ther
August 2007
Article Synopsis
- Atypical antipsychotic drugs (APDs) target dopamine D(2) receptors but have side effects like motor deficits and cognitive dulling; newer APDs with additional effects on serotonin receptors (5-HT(2A)) show better efficacy.
- ACP-103 is a novel compound that acts as a selective 5-HT(2A) inverse agonist without affecting D(2) receptors, aiming to enhance therapeutic effects while minimizing side effects.
- Research indicates that ACP-103 can improve the effectiveness of other APDs and reduce unwanted side effects associated with them, suggesting its potential as a beneficial adjunctive treatment.
